Research programme: cancer therapeutics - Oncoceutics

Drug Profile

Research programme: cancer therapeutics - Oncoceutics

Alternative Names: Imipridone compounds - Oncoceutics; ONC 202; ONC 206; ONC 212; ONC 222; ONC 235; ONC 400

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncoceutics
  • Class Small molecules
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; Proto oncogene protein c-akt inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Ewing's sarcoma

Most Recent Events

  • 13 Oct 2017 Oncoceutics and The University of Texas MD Anderson Cancer Center expands research collaboration agreement for the clinical development of ONC 212 for Acute myeloid leukaemia
  • 09 Oct 2017 Oncoceutics plans a phase I and phase II trial of ONC 212 for Acute myeloid leukaemia
  • 14 Mar 2017 Oncoceutics expands research collaboration with NIH for Cancer therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top